Capelle Aan Den Ijssel

The BioDay Registry collects real-world data on the safety and effectiveness of new systemic treatments such as biologics and Janus kinase inhibitors in patients with atopic dermatitis. It also investigates how these treatments affect other related allergic conditions like food allergies, asthma, and conjunctivitis. This multicenter registry aims to provide valuable information for daily clinical practice. The registry includes several modules focused on different atopic comorbidities to capture comprehensive patient data during biologic treatment. It observes patients treated with new systemic therapies over time in a real-world setting without assigning specific interventions. Participants provide information through questionnaires and regular assessments to track treatment effects and side effects. Researchers monitor changes from baseline at several time points, including 16 weeks, 1 year, and 2 years, and analyze how long patients continue their prescribed treatments. The study includes both adults and children and follows them prospectively to gather long-term safety and effectiveness data.

Researchers are investigating ways to preserve the rectum in patients with rectal cancer who respond well to initial treatments like chemotherapy and radiation. This phase II feasibility study focuses on patients with intermediate or locally advanced rectal cancer who show a good but not complete clinical response after neoadjuvant (chemo)radiation. The goal is to see which additional local treatments—contact x-ray brachytherapy or extending the waiting period with or without local excision—can help preserve the organ and avoid major surgery. The study compares two treatment approaches. In the first arm, patients receive contact x-ray brachytherapy, which delivers targeted radiation in three sessions spaced two weeks apart, starting within 14 weeks after completing initial therapy. In the second arm, the waiting period is extended by 6 to 8 weeks, followed by reassessments; if a small tumor remains, local excision is offered using minimally invasive surgery. Patients with a complete clinical response during follow-up enter a watch-and-wait program, while those with disease progression may need standard surgery. Participants will undergo regular evaluations including radiological and endoscopic assessments every three months to monitor treatment response. The main measure of success is the rate of organ preservation one year after randomization, defined as keeping the rectum intact without a stoma or cancer recurrence. Safety, side effects, and long-term outcomes will also be tracked over several years. Patients not eligible for randomization may join an observational registry to further understand treatment effects.

Researchers are evaluating a personalized patient-centered surveillance program for individuals who have undergone surgery for non-metastatic colorectal carcinoma. This program aims to improve quality of life and reduce stress by shifting much of the follow-up care from hospital visits to the home setting. The study compares this home-based follow-up to the standard care over a 36-month period, focusing on health-related quality of life and the number of hospital visits. The follow-up includes monitoring blood levels of CEA using an automatic capillary blood withdrawal device every six months for the first two years and annually thereafter. Vital signs are measured remotely every three months for the first two years and every six months afterward using a multi-parameter monitoring system. Quality of life is assessed regularly through questionnaires on the same schedule as vital sign checks. One hospital visit for medical imaging is scheduled one year after surgery in accordance with national guidelines. Participants will complete questionnaires and have their blood and vital signs monitored from home throughout the study. Researchers will measure quality of life using standardized tools and track hospital visits over 36 months. The study also adapts to any updates in national guidelines and includes safety monitoring through scheduled evaluations and remote data collection.

Researchers are studying patients diagnosed with colorectal cancer, small bowel cancer, and anal cancer to better understand factors that affect treatment outcomes and survival. This study looks beyond tumor stage to explore how biochemical, genetic, environmental, and clinical factors may influence tumor recurrence and patient survival. It aims to address the gap in knowledge caused by most cancer patients not participating in clinical trials, and to validate trial results in a broader patient population. This is a prospective observational cohort study where data is collected from patients starting at their primary diagnosis and continuing until death. After informed consent, researchers gather detailed information on medical history, clinical status, imaging, pathology, tumor characteristics, treatments, hospital stays, side effects, and adverse events. Additional consent allows collection of patient-reported outcomes on quality of life and work ability, as well as biological materials like blood and tumor tissue for research and biobanking. Participants will be closely followed over time with ongoing data collection on treatment effects, clinical outcomes, and patient experiences. The study aims to provide accurate real-world data on various treatments and outcomes and to serve as a resource for future research into prognostic markers, new therapies, molecular studies, and health care policy. The main outcome measured is progression-free survival, tracked for up to 10 years, to better understand long-term treatment impact.